Video Session 1: Vaginal and Vulvar Cancer

ESGO eAcademy, Faculty / Presenters, 4193844

Management of Oligometastatic Recurrent Disease in Ovarian Cancer

ESGO eAcademy, Faculty / Presenters, 4193846

Discussion

ESGO eAcademy, Faculty / Presenters, 4193528

Discussant

ESGO eAcademy, Alejandra Martinez, 4193524

Extended follow-up of survival outcomes after a nationwide adoption of robotic minimally invasive surgery for early-stage cervical cancer in denmark - an update

ESGO eAcademy, Tine Schnack, 4193523

Immunotherapy in Gynaecologic Cancer - What’s around the Corner?

ESGO eAcademy, Alexandra Leary, 4193527

Preoperative Work-Up; Primary Treatment Early Stage; Primary Treatment Advanced Stage

ESGO eAcademy, Ben Davidson, 4193512

Old and new risk classification system for endometrial cancer: which predicts recurrence better?

ESGO eAcademy, Tommaso Occhiali, 4193522

Ovarian Cancer and Immunotherapy - Can We Make it Successful?

ESGO eAcademy, Anniina Färkkilä, 4193526

No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinomas

ESGO eAcademy, Famke Wakkerman, 4193521

Introduction and General Recommendations

ESGO eAcademy, Faculty / Presenter(s), 4193507

Current and Future Landscape of Immunotherapy

ESGO eAcademy, Faculty / Presenters, 4193843

Best Oral Session 1: Endometrial and Cervical Cancer

ESGO eAcademy, Faculty / Presenters, 4193842

New ESGO Ovarian Cancer Guidelines: Practical Applications through Tumour Board Simulation and Updated Care Algorithms - part I

ESGO eAcademy, Faculty / Presenters, 4193841

Current Landscape of Immunotherapy - Mind the Gap

ESGO eAcademy, Hanna Dahlstrand, 4193525

Introduction and General Recommendations

ESGO eAcademy, Anna Fagotti, 4193508

Interim analysis of ultrasound-guided sentinel lymph node assessment in robotic surgery for uterine cancer: the R-LYNUS prospective study

ESGO eAcademy, Elena Teodorico, 4193520

Discussion

ESGO eAcademy, Faculty / Presenters, 4193499

Future Directions of Second Line Therapy of Endometrial Cancer

ESGO eAcademy, Shibani Nicum, 4193498

How Does (Neo-)Adjuvant Therapy Influence First Line Therapy of Recurrent Endometrial Cancer?

ESGO eAcademy, Christian Marth, 4193497

Navigating the Course of Advanced Ovarian Cancer Maintenance Therapy with Current and Emerging Biomarkers

ESGO eAcademy, Faculty / Presenters, 4193839

What Is the Role of Angiogenesis in Endometrial Cancer?

ESGO eAcademy, Frederik Marmé, 4193496

Non-Chemo Combination Treatments in Gynaecological Cancers

ESGO eAcademy, Faculty / Presenters, 4193838

Optimizing Management in Platinum-Resistant Ovarian Cancer: From Early Diagnosis to Strategic and Targeted Treatment Sequencing

ESGO eAcademy, Faculty / Presenters, 4193840

Hall D2 26-feb

ESGO eAcademy, Faculty / Presenters, 4193381

Hall D1 28-feb

ESGO eAcademy, Faculty / Presenters, 4193380

Hall D1 27-feb

ESGO eAcademy, Faculty / Presenters, 4193379

Hall D1 26-feb

ESGO eAcademy, Faculty / Presenters, 4193378

Interactive Colposcopy Cases

ESGO eAcademy, Grigore Mihaela, 4200132

Uterine Sarcoma

ESGO eAcademy, Elisabeth Epstein, 4194644

Interactive Colposcopy Cases

ESGO eAcademy, Vesna Kesic, 4200131

MUSA Terms, Definitions and Measurements to Describe the Sonographic Features of Myometrium and Uterine Masses

ESGO eAcademy, Thierry Van den Bosch, 4194643

Vaccination after CIN and Cancer Treatments

ESGO eAcademy, Joanna Kacperczyk-Bartnik, 4200129

Impact of recent antibiotic exposure on gut microbiome dynamics and clinical outcomes in gynecologic cancer patients receiving immune checkpoint inhibitors

ESGO eAcademy, Hyun-Jin Choi, 4200122

Swiss-GO-08/OV-PRECISION: A randomized controlled swiss trial examining the benefit of multimodal guided therapy in ovarian cancer.

ESGO eAcademy, Francis Jacob, 4200121

Vaccination after Cervical Treatment – The NOVEL Trial

ESGO eAcademy, Maria Kyrgiou, 4200128

Endometrial Cancer Staging

ESGO eAcademy, Elisabeth Epstein, 4194642

New HPV Vaccines

ESGO eAcademy, Elmar Joura, 4200127

WomEC, a novel IVD for endometrial cancer diagnosis

ESGO eAcademy, Marina Rigau, 4200118

Metabolomic signatures of molecular classes in endometrial cancer with a focus on TP53-mutant tumors

ESGO eAcademy, Zehra Ozcelebi, 4200117

IETA Terms, Definitions and Measurements to Describe the Sonographic Features of the Endometrium and Intrauterine Lesions

ESGO eAcademy, Thierry Van den Bosch, 4194641

AUD 10-11-12 26-feb

ESGO eAcademy, Faculty / Presenters, 4193384

Clinical and prognostic impact of the MELF pattern of invasion in endometrioid endometrial carcinoma: A retrospective multivariable evaluation of histopathologic and molecular correlates

ESGO eAcademy, Tunç Timur, 4200116

ESGO 2026 - Congress invitation

ESGO eAcademy, Faculty / Presenter(s), 4168940

Anal Intraepithelial Neoplasia Management and Follow-up during HPV Screening

ESGO eAcademy, Vesna Kesic, 4200126

Vulvar Cancer: A Globall Call for VSE

ESGO eAcademy, Mario Preti, 4200125

Exploiting the Immunomodulatory Effects of PI3K/mTOR Inhibitors to Overcome Immune Checkpoint Blockade Resistance in Leiomyosarcoma

ESGO eAcademy, Wout De Wispelaere, 4200114

From Ascites to Precision Medicine: Ascitoid Models and Extracellular Vesicles in Ovarian Cancer

ESGO eAcademy, Vendula Hlavackova Pospichalova, 4200113

Management of CIN2: To Treat or Not to Treat

ESGO eAcademy, Maria Kyrgiou, 4200124

Tumor-Infiltrating Lymphocytes Correlate with Response to First-Line Platinum-Based Chemotherapy in a Real-World Ovarian Cancer Cohort

ESGO eAcademy, Vit Weinberger, 4200112

ISUOG Consensus Statement on Sonographic Assessment of the Endometrium: How to Perform a Gynaecological Ultrasound Scan and Report Findings

ESGO eAcademy, Thierry Van den Bosch, 4194640

New HPV Screening Methods, DNA, mRNA and Self Tests

ESGO eAcademy, Marc Arbyn, 4200123

Introduction on the Role of Imaging in ESGO-ESP-ESTRO Endometrial Carcinoma Guidelines (update 2025) and the ESGO-EURACAN-GCIG Uterine Sarcoma Guidelines, and related consensus statements

ESGO eAcademy, Daniela Fischerova, 4194639

ESGO TransLink Repository

ESGO eAcademy, Viola Heinzelmann, 4200111

TransLink Introduction

ESGO eAcademy, Viola Heinzelmann, 4200359

Prevention Introduction

ESGO eAcademy, Murat Gultekin, 4200360

Submit your video

ESGO eAcademy, Faculty / Presenters, 4194264

Patient Advocate

ESGO eAcademy, Faculty / Presenter(s), 4194074

Vaginal & Vulvar cancer

ESGO eAcademy, Faculty / Presenter(s), 4194073

Ovarian cancer

ESGO eAcademy, Faculty / Presenter(s), 4194072

Endometrial cancer

ESGO eAcademy, Faculty / Presenter(s), 4194071

Cervical cancer

ESGO eAcademy, Faculty / Presenter(s), 4194070

Meet the Surgeon: Urinary Fistula after Surgery

ESGO eAcademy, Faculty / Presenters, 4192291

Liver metastasis resection complicated by right hepatic vein injury: control and repair

ESGO eAcademy, Faculty / Presenters, 4193415

ESGO-INCIP Guidelines for the management of patients with gynaecological cancers during pregnancy

ESGO eAcademy, Faculty / Presenters, 4188283

Phenix Trial Presentation

ESGO eAcademy, Faculty / Presenter(s), 4193446

Access

ESGO eAcademy, Faculty / Presenter(s), 4192925

Tumour Board Webinar: Management of lower Squamous Tumours Vulvar and Vaginal

ESGO eAcademy, Faculty / Presenters, 4192621

Colposcopy Uncovered: Past, Present, and Future in Cervical Cancer Prevention and Innovation

ESGO eAcademy, Faculty / Presenters, 4192760

Meet the surgeon: Biggest Achievements in Surgery – Personalized Surgical Management

ESGO eAcademy, Faculty / Presenters, 4174355

ASYGO - ENYGO 1st Joint Webinar: Training and Surgical Educatuion in Gyneacologic Oncology

ESGO eAcademy, Faculty / Presenters, 4194178

Challenges in biomarker-driven treatment approaches

ESGO eAcademy, Faculty / Presenter(s), 4192723

Biomarker-driven clinical approaches beyond molecular subgroups

ESGO eAcademy, Faculty / Presenter(s), 4192722

None-MMRd: NSMP, the biggest and least specific?

ESGO eAcademy, Faculty / Presenter(s), 4192721

None-MMRd: p53 abnormal, the worst

ESGO eAcademy, Faculty / Presenter(s), 4192720

None-MMRd: POLEmut, the best

ESGO eAcademy, Faculty / Presenter(s), 4192719

MMRd, the most clear molecular subgroup?

ESGO eAcademy, Faculty / Presenter(s), 4192718

Risk group stratification (including FIGO 2023 staging)

ESGO eAcademy, Faculty / Presenter(s), 4192717

The hereditary endometrial cancer - Lynch syndrome

ESGO eAcademy, Faculty / Presenter(s), 4192716

Integrating it all: AI and machine learning in endometrial carcinoma

ESGO eAcademy, Faculty / Presenter(s), 4192715

“Synchronous” tumours: are they synchronous?

ESGO eAcademy, Faculty / Presenter(s), 4192714

LVSI: no/focal/substantial. How to determine, to cluster und to guide treatment? Implications according to ESGO-ESTRO-ESP GLs

ESGO eAcademy, Faculty / Presenter(s), 4192713

LVSI: no/focal/substantial. How to determine, to cluster und to guide treatment? The pathological point of view

ESGO eAcademy, Faculty / Presenter(s), 4192712

LVSI: no/focal/substantial. How to determine, to cluster und to guide treatment? The clinical experience

ESGO eAcademy, Faculty / Presenter(s), 4192711

Biomarkers beyond Molecular classification: ER/PR, HER2, Trop2 and many more – what, when, how and why to test?

ESGO eAcademy, Faculty / Presenter(s), 4192710

The game-changer: Molecular classification of Endometrial carcinomas

ESGO eAcademy, Faculty / Presenter(s), 4192709

Molecular pathology and clinical implications in clear cell

ESGO eAcademy, Faculty / Presenter(s), 4192708

Integration of molecular pathology to define patients for fertility sparing management in endometrial and ovarian tumours: too early?

ESGO eAcademy, Faculty / Presenter(s), 4192707

Molecular/genetic pathways and treatment of low-grade ovarian tumours

ESGO eAcademy, Faculty / Presenter(s), 4192706

Heterogeneity and immunobiology of OC and impact on IO resistance in OC

ESGO eAcademy, Faculty / Presenter(s), 4192705

Tumour profiling analysis of mucinous OC and possible therapeutic implications

ESGO eAcademy, Faculty / Presenter(s), 4192704

Her-2 amplification in OC: which expectations for therapy?

ESGO eAcademy, Faculty / Presenter(s), 4192703

Targeting folate receptor alpha in OC: future prospectives, other than the pl-resistant setting.

ESGO eAcademy, Faculty / Presenter(s), 4192702

Are all HRD+ OC platinum and PARP sensitive? And why do some HRD- OC respond so well?

ESGO eAcademy, Faculty / Presenter(s), 4192701

HRD test: pitfalls and new possible approach

ESGO eAcademy, Faculty / Presenter(s), 4192700

Do liquid biopsies have a role to play in diagnosis and monitoring in ovarian cancer?

ESGO eAcademy, Faculty / Presenter(s), 4192699

Artificial intelligence in ovarian cancer histopathology

ESGO eAcademy, Faculty / Presenter(s), 4192698

Secondary prevention in OC: is it possible?

ESGO eAcademy, Faculty / Presenter(s), 4192697

Precursor lesions of high grade serous carcinoma: genomic features and possible therapeutic implications

ESGO eAcademy, Faculty / Presenter(s), 4192696

Oncogenetics in Focus: From Risk to Prevention in Women’s Cancers

ESGO eAcademy, Faculty / Presenters, 4173963